Literature DB >> 21742799

Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome.

Markus Britschgi1, Kaspar Rufibach, Sarah L Bauer Huang, Christopher M Clark, Jeffrey A Kaye, Ge Li, Elaine R Peskind, Joseph F Quinn, Douglas R Galasko, Tony Wyss-Coray.   

Abstract

The study of chronic brain diseases including Alzheimer's disease in patients is typically limited to brain imaging or psychometric testing. Given the epidemic rise and insufficient knowledge about pathological pathways in sporadic Alzheimer's disease, new tools are required to identify the molecular changes underlying this disease. We hypothesize that levels of specific secreted cellular signaling proteins in cerebrospinal fluid or plasma correlate with pathological changes in the Alzheimer's disease brain and can thus be used to discover signaling pathways altered in the disease. Here we measured 91 proteins of this subset of the cellular communication proteome in plasma or cerebrospinal fluid in patients with Alzheimer's disease and cognitively normal controls to mathematically model disease-specific molecular traits. We found small numbers of signaling proteins that were able to model key pathological markers of Alzheimer's disease, including levels of cerebrospinal fluid β-amyloid and tau, and classify disease in independent samples. Several of these factors had previously been implicated in Alzheimer's disease supporting the validity of our approach. Our study also points to proteins which were previously unknown to be associated with Alzheimer's disease thereby implicating novel signaling pathways in this disorder.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742799      PMCID: PMC3205866          DOI: 10.1074/mcp.M111.008862

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  38 in total

1.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

2.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

3.  Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.

Authors:  Michael T Wunderlich; Thorsten Hanhoff; Michael Goertler; Friedrich Spener; Jane F C Glatz; Claus-W Wallesch; Maurice M A L Pelsers
Journal:  J Neurol       Date:  2005-04-18       Impact factor: 4.849

4.  A serum protein-based algorithm for the detection of Alzheimer disease.

Authors:  Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; Rachelle Doody; Thomas Fairchild; Perrie Adams; Steven Waring; Ramon Diaz-Arrastia
Journal:  Arch Neurol       Date:  2010-09

Review 5.  Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-07-22       Impact factor: 17.088

6.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors:  Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

9.  Metabonomic, transcriptomic, and genomic variation of a population cohort.

Authors:  Michael Inouye; Johannes Kettunen; Pasi Soininen; Kaisa Silander; Samuli Ripatti; Linda S Kumpula; Eija Hämäläinen; Pekka Jousilahti; Antti J Kangas; Satu Männistö; Markku J Savolainen; Antti Jula; Jaana Leiviskä; Aarno Palotie; Veikko Salomaa; Markus Perola; Mika Ala-Korpela; Leena Peltonen
Journal:  Mol Syst Biol       Date:  2010-12-21       Impact factor: 13.068

10.  The impact of cellular networks on disease comorbidity.

Authors:  Juyong Park; Deok-Sun Lee; Nicholas A Christakis; Albert-László Barabási
Journal:  Mol Syst Biol       Date:  2009-04-07       Impact factor: 11.429

View more
  21 in total

Review 1.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  Microglial priming in Alzheimer's disease.

Authors:  Jun-Wei Li; Yu Zong; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

3.  Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.

Authors:  Benoit Lehallier; Laurent Essioux; Javier Gayan; Roxana Alexandridis; Tania Nikolcheva; Tony Wyss-Coray; Markus Britschgi
Journal:  JAMA Neurol       Date:  2015-12-14       Impact factor: 18.302

Review 4.  Maternal immune activation and abnormal brain development across CNS disorders.

Authors:  Irene Knuesel; Laurie Chicha; Markus Britschgi; Scott A Schobel; Michael Bodmer; Jessica A Hellings; Stephen Toovey; Eric P Prinssen
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 5.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

6.  Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.

Authors:  Jeanine R Jarnes Utz; Thomas Crutcher; Joseph Schneider; Patrick Sorgen; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2014-12-06       Impact factor: 4.797

7.  How predictive of dementia are peripheral inflammatory markers in the elderly?

Authors:  Andrea L Metti; Jane A Cauley
Journal:  Neurodegener Dis Manag       Date:  2012-12-01

8.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

9.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-17       Impact factor: 5.270

Review 10.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.